



The Role of IL-18 and Human Cytomegalovirus in Type 1 Diabetes Mellitus in Thi-Qar Province

Ali G. Ammar¹, Mohaned H. Mahmood Al-Izzi¹, Hind M. Mousa²

¹ Department of Biology, College of Sciences, Tikrit University, Tikrit, Iraq

² College of Science, University of Thi-Qar, Thi-Qar, Iraq

DOI: <http://dx.doi.org/10.25130/tjps.26.2021.004>

ARTICLE INFO.

Article history:

-Received: 10 / 12 / 2020

-Accepted: 26 / 12 / 2020

-Available online: / / 2020

Keywords: Type I diabetic mellitus (T1DM), cytomegalovirus (CMV) and Interleukin-18 (IL-18)

Corresponding Author:

Name: Ali G. Ammar

E-mail: raqr3880@gmail.com

mohanadmahmood2016@yahoo.com

Hindmousa_pa@sci.utq.edu.iq

Tel:

ABSTRACT

Previous studies indicated that elevated serum levels of Interleukin - 18 (IL-18) and human cytomegalovirus (HCMV) antibodies have a fundamental role in the pathogenesis of Type I diabetic mellitus T1DM. Therefore, the aim of the current study was to investigate the possible overlap between human cytomegalovirus (HCMV) and Interleukin-18 (IL-18) with the pathogenesis of T1DM. The serum of (45) T1DM patients and (45) healthy controls were used to detect IL-18 levels with an ELISA Kit and detect HCMV with cobas c411 apparatus for detect IgM and IgG HCMV.

The results showed that the levels of IL-18 and human CMV IgM, IgG were significantly higher in patients with type 1 diabetes compared to the control group (45.8773 $\pm$ 12.196 and 0.52 $\pm$ 0.25, 63.52 $\pm$ 13.0 pg/ml for patients respectively) versus (12.611 $\pm$ 3.9 and 0.11 $\pm$ 0.01, 0.261 $\pm$ 0.68 pg/ml for healthy subjects, respectively); The values were at P value $\leq$ 0.05.

The results of the data concluded that there was a significant increase of IL-18 and human CMV IgM, IgG in the serum of the patient group compared to the lower levels in the control group, indicating that these markers may be involved in the pathogenesis and development of T.

These data concluded that there was a significant increase in serum IL-18 and HCMV Abs, compared to the lower levels in the control group, indicating that these markers may be involved in the pathogenesis and development of T1DM.

Introduction

Type 1 diabetes mellitus (T1DM) is one of the most common chronic diseases that occur during childhood and accounts for about 10% of all cases of diabetes. In this disease, the insulin-producing from beta-cells located in the pancreas are gradually destroyed until the amount of insulin produced is not sufficient to keep up a normal level of blood glucose [1]. T1DM is an autoimmune disease, which reveals the role of immune response effectors in the pathogenic processes and failure of immune tolerance towards β -cell antigen [2]. The pathogenesis of T1DM is complex and results from a combination of genetic and environmental factors. Among environmental factors a series of viruses including cytomegalovirus (CMV) infections have been associated with the development of beta cell autoimmunity [3]. CMV infection is already relatively common among small

children. In the Finnish population, 27% of infants at the age of 7 months tested positive for CMV IgG antibodies [4].

CMV is a common herpes group virus that causes a lifelong latent infection. CMV seroprevalence in adults varies geographically from 40 % to 100 % [5]. In Finland, similar to other Western countries, approximately 50% of pregnant women have seropositive for CMV- specific IgG antibodies [6]. More than 75 % of childhood CMV infections are acquired in early childhood, transmitted typically perinatally or during the first year of life through saliva, maternal genital secretions or breast milk after reactivation of the latent virus in the mother. Thereafter, the incidence rate of CMV infection, stays rather stable until it peaks again at the age of 4 to 5 years [4].

(HCMV) belonging to the Betaherpesvirinae subfamily, is the largest member of the the human herpesvirus family [7]. In the fetus, newborns, and immunocompromised patients, HCMV infection can cause a range of severe clinical effects [8-10]. HCMV is one of the important viral factors that are believed to be linked with the occurrence of T1D because of its ability to induce the immunological damage of β -cells [11].

(CMV) is an important factor believed to be associated with type 1 diabetes due to its role in stimulating damage to immune beta cells (beta cells) [12].

Evidence supporting the role of inflammation in type 1 and type 2 diabetes had increased, the mechanism of inflammation process involved the release of inflammatory cells, and cytokines profibrotic growth factors recording interleukin-1 (IL-1), interleukin-18 (IL-18), interleukin-6 (IL-6) [13]. Interleukin-18 (IL-18) considers as a proinflammatory cytokine (member of the IL-1 cytokine super family) that secreted from mononuclear and plays an essential role in many inflammatory and autoimmune diseases [14].

A previous study by [15] indicated that high levels of IL-18 in type 1 DM patients are associated with short- and long-term glycemic control.

In Iraq, Study for [16] emphasized that IL-18 has a critical role in the initiation, development, and promotion of T1DM and T2DM in Iraqi patients. Also, Study for [17] indicated that infectious diseases are more common and / or serious in people with diabetes, which raises their mortality rate.

Interleukin (IL) -18 is a pro-inflammatory cytokine that has been involved in causing a number of inflammatory diseases like type 1 diabetics [18]. IL-18 has also been recorded to be included in the pathogenesis and promotion of diabetes [19].

An elevation IL-18 levels have been indicated in the sera of patients at high risk for developing T1D [20]. Yaribeygi *et al.* (2019) study reported that interleukin 18 and other pro-inflammatory cytokines are increased by hyperglycemia in subjects with impaired glucose tolerance, suggesting a causal role for hyperglycemia in the immune activation of diabetes [13].

This study was designed to compare the circulation serum levels of IL-18 and HCMV Abs between type1 diabetes and healthy to detect the crucial role of these markers in pathogenicity of T1DM.

Material and Methods

A total of 45 T1D patients, who attended The Special Center for Endocrine Glands and Diabetes in Al-Nassryieh city in Thi-Qar province, Iraq in-addition to (45) apparently non-diabetic healthy people representing the control group. This case-control study was conducted from September 2019- May 2020. The patients are diagnosed as by the consultant medical staff, according to checked clinical examination and biochemical analysis. The patients

divided into (23) males and (22) females with age range from 1-40 years. The control included (22) males and (23) females within the same age range of patients group. Five ml of venous blood was drawn from each subject (diabetic patients and controls). The blood samples were collected in coagulates gel tubes and left to clot at room temperature and then centrifuged at 3000 rpm for 10 minutes to separate the serum. The serum samples were separated in several 1.0 ml tubes that were stored frozen at -20°C until used to avoid thawing and repeated freezing.

IL-18 levels measurement was quantitatively determined in sera of patients and healthy control subjects by means of ELISA (Enzyme Linked Immunosorbent Assay) using ready kits manufactured by Bioassay company(China), While CMV IgM & IgG levels measurement by Cobas c411 automated instrument.

To conduct the research ethical permission was obtained from the hospital and from all participants in this work patients and healthy. The patients Selection were accomplished with the assistance of Physicians in the hospitals.

Statistical analysis

The statistical analysis of this case-control study was performed with the statistical package for social sciences (SPSS) 20.0 and Microsoft Excel 2013. Numerical data with normal distribution were described as mean and standard deviation, independent sample T-test used for comparison between two groups. Categorical data were described as count and percentage. The lower level of accepted statistically significant difference is below or equal to 0.05 and the high level of accepted statistically significant difference is below or equal to 0.01.

Results and Discussion

1. Distribution of type 1 diabetes patients by gender:

Regarding to gender distribution, the results showed that the percentage of males in the T1D patient group was 23(51.11%) and the percentage of females was 22(48.89%), where the ratio of male to females was 1.05: 1. The persons in the control group were chosen similar to the gender percentage of the patient group to avoid having this factor effect on the quality of the study. The percentage of the males and females in the control group was 22(48.89%) and 23(51.11%), respectively. As explained in the below Table (1).

Table 1: Distribution of the two Study Groups by Gender:

Gender		Study group		
		T1DM Patients	Control Groups	Total
Male	Count	23	22	45
	%	51.11	48.89	100
Female	Count	22	23	45
	%	48.89	51.11	100

The present data was compatible with Hussein *et al.* (2016) in Baghdad province who showed that Male to female ratio was 1.058:1 [21].

Also, The study was relatively agreed with two Iraqi studies by Majeed (2008) in Thi-Qar province and Saleh *et al.* (2012) where both studies showed that Male to female ratio was 1.2:1 [22,23]. The finding by Matteo Apicella *et al.* (2020) indicated that Male percentage was 51%, and female was 49% [24]. But the current results incompatible with El-sehmawy and his colleagues (2019) who found that Male and female percentage was male 47.5%, female 52.5% [25]. Also, Thomas *et al.* (2003) demonstrated that male to female ratio was 0.89:1 [26]. In our current study, we made sure that both groups of the study were identical in terms of the number of samples and gender to avoid the influence of the sex factor on the study criteria. So according to the current results that support previous data we conclude there is no significant effect to the gender on diabetics type I.

2. Distribution of type 1 diabetes patients according to age groups

The results indicated that there was a significant decrease in T1D 1 patient percentage in third age of patients with a percentage 11.11% for the age group (21 -30) years, while the highest incidents of T1D 1 were in second age group with a percentage 33.33 % for the age group (11-20) years. Compared to the control group, which showed decreases in the second group with a percentage 17.77 % and increase in the first and third groups with a percentage (28.89%). As listed below in the Table (2) below.

Table 2: Distribution of the two study groups by age groups.

Age groups (Years)	Study group			
	T1DM Patients		Control Groups	
	Count	%	Count	%
(1-10)	14	31.11%	13	28.89%
(11-20)	15	33.33%	8	17.77%
(21-30)	5	11.11%	13	28.89%
(31-40)	11	24.45%	11	24.45%
Total	45	100%	45	100%

Age mean + SD = 16.9 ± 10.9 , Min = 1 year & Max = 40 year

The current finding was compatible with Nuha *et al.* (2016) who found that the high frequency onset of T1D was recorded at the child hood before the age of puberty [27]. Also, the study was compatible with the Majeed. (2008) in Thi-Qar province who noted that the majority of patients (79,3%) were between 5-12 years of age [22]. Derraik *et al.* (2012) found that increasing incidents of Type I were recorded in age group (10-14) years [28]. This age range was in agreement with the study of Wherrett *et al.* (2000) who found that T1D recorded at this childhood stage [29].

3. The levels of IL-18 in patients and Healthy:

According to the levels of IL-8, the study results recorded a significant increase in the values of IL-18, where the values were (45.8773 ± 12.196), As a comparison with a control group with values (12.611± 3.9). As the study showed a significant difference between IL-18 in patients with type 1 diabetes. These results also showed that there were statistical significant differences at $p < 0.01$ in the

levels of IL-18 in patients and healthy. As shown in the Table (4-5) below.

Table 3: Sera levels of IL-18 in patients and healthy.

Groups	IL 18 Mean± SD
Patient	45.8773±12.196
Control	12.611± 3.9
T value	17.427
Sig.	0.001

Regarding to the IL-18 results, the findings were high compatible with Dong *et al.* (2007) also compatible with Harms *et al.* (2015) who found that IL-18 is significantly increased in the sera of juvenile T1Ds compared to controls [30,18]. Esposito *et al.* (2002) demonstrated that IL-18 and other proinflammatory cytokines are increased by hyperglycemia in subjects with impaired glucose tolerance, suggesting a causal role for hyperglycemia in the immune activation of diabetes [31].

4. Level HCMV IgM and HCMV IgG in study groups:

The study showed a significant increase in the values of HCMV IgM and HCMV IgG, where the values were (0.52 ± 0.25) and (63.52 ± 13.0) respectively, as a comparison with a control group, the values were (0.11 ± 0.01) and (0.261 ± 0.68) respectively. These results also showed that there were statistical significant differences at $p \leq 0.01$ in the levels of HCMV IgM and HCMV IgG in patients and healthy, as shown in the Table (4) below.

Table 4: Levels of HCMV IgM and HCMV IgG in study groups.

Groups	HCMV IgM Mean± SD	HCMV IgG Mean± SD
Patient	0.52 ± 0.25	63.52 ± 13.0
Control	0.11 ± 0.01	0.261 ± 0.68
T value	10.77	32.465
Sig.	< 0.0001	< 0.0001

The present finding appeared compatibility with Yasir *et al.* (2013) for results of the levels of HCMV IgM in Najaf [32]. The study also agreed with Ahmad *et al.* (2014) in Khartoum and Abdel-Moneim *et al.* (2017) in Egypt for results of the levels of HCMV IgG [33,34]. On the other hand, Where the study showed incompatible with Ibrahim Saber & Mohammed (2019) for results of the levels of HCMV IgM and HCMV IgG [12]. The current result was inconsistent with Al-Hakami *et al.* (2016) the rise in CMV (IgM) in type 1 diabetic patients [35], and it was non-compatible with Aarnisalo *et al.* (2008) for results of the levels of HCMV IgG [36]. A study by Dedinská *et al.* (2016) revealed the existence of anti-HCMV IgM antibody in these patients in conjunction with the onset of the disease and presence of hyperglycemia and elevation of HbA1c might suggest the role of the asymptomatic HCMV infection with the development of T1D [37]. A study reported cytomegalovirus (CMV) do appear to be somehow associated with autoimmune type 1 diabetes since

there is a strong correlation between the presence of islet cell autoantibodies and persistent infections [38]. These findings indicate that the immunoresponse caused by HCMV infection was associated with b cell injury [39].

References

[1] Atkinson, M. A. (2012). The pathogenesis and natural history of type 1 diabetes. *Cold Spring Harbor perspectives in medicine*, 2(11), a007641.

[2] Li, M., Song, L. J., & Qin, X. Y. (2014). Advances in the cellular immunological pathogenesis of type 1 diabetes. *Journal of cellular and molecular medicine*, 18(5), 749-758.

[3] Jun, H. S., & Yoon, J. W. (2004). A new look at viruses in type 1 diabetes. *ILAR journal*, 45(3), 349-374.

[4] Aarnisalo, J., Ilonen, J., Vainionpää, R., Volanen, I., Kaitosaari, T., & Simell, O. (2003). Development of antibodies against cytomegalovirus, varicella-zoster virus and herpes simplex virus in Finland during the first eight years of life: a prospective study. *Scandinavian journal of infectious diseases*, 35(10), 750-753.

[5] Cannon, M. J., Schmid, D. S., & Hyde, T. B. (2010). Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Reviews in medical virology*, 20(4), 202-213.

[6] Alanen, A., Kahala, K., Vahlberg, T., Koskela, P., & Vainionpää, R. (2005). Seroprevalence, incidence of prenatal infections and reliability of maternal history of varicella zoster virus, cytomegalovirus, herpes simplex virus and parvovirus B19 infection in South-Western Finland. *BJOG: An International Journal of Obstetrics & Gynaecology*, 112(1), 50-56.

[7] Haaheim, L. R., Pattison, J. R., & Whitley, R. J. (Eds.). (2002). *A practical guide to clinical virology*. John Wiley & Sons.

[8] Boeckh, M., Nichols, W. G., Papanicolaou, G., Rubin, R., Wingard, J. R., & Zaia, J. (2003). Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. *Biology of Blood and Marrow Transplantation*, 9(9), 543-558.

[9] Gandhi, M. K., & Khanna, R. (2004). Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. *The Lancet infectious diseases*, 4(12), 725-738.

[10] Adler, S. P., Nigro, G., & Pereira, L. (2007, February). Recent advances in the prevention and treatment of congenital cytomegalovirus infections. In *Seminars in perinatology* (Vol. 31, No. 1, pp. 10-18). WB Saunders.

[11] Kaur, K. K. (2020). Attempting Getting Insulin Independent Immunotherapies in Type 1 Diabetes Mellitus (T1D) in the Pre-Stage 1 (Before Islet Autoantibodies). *Acta Scientific Paediatrics*, 3, 01-04.

Conclusion

According to these results, the current study concluded that IL-18 and (HCMV) infections may have a role in the pathogenesis, development and progression of Type 1 diabetes mellitus in Iraqi patients of Thi-Qar province.

[12] Ibrahim Saber A-Z A-B, Mohammed AH (2019): The role of Human Cytomegalovirus and Epstein-Barr virus in type 1 Diabetes Mellitus, *Ann Trop & Public Health*; 22(9): S267.

[13] Yari beygi, H., Atkin, S. L. and Sahebkar, A. (2019) Interleukin-18 and diabetic nephropathy: A review, *Journal of cellular physiology*, 234(5), pp. 5674–5682.

[14] Nariai, Y., Kamino, H., Obayashi, E., Kato, H., Sakashita, G., Sugiura, T., ... & Kadomatsu, K. (2019). Generation and characterization of antagonistic anti-human interleukin (IL)-18 monoclonal antibodies with high affinity: two types of monoclonal antibodies against full-length IL-18 and the neoepitope of inflammatory caspase-cleaved active IL-18. *Archives of biochemistry and biophysics*, 663, 71-82.

[15] Toma, V., Cioloca, D. P., Forna, D. A., Hurjui, L., Botnariu, G. I., Nechifor, I. E., ... & Holban, C. (2016). IL 18 as an important gingival inflammatory biochemical marker in children and adolescents with insulin-dependent diabetes mellitus. *Rev. Chim. (Bucharest)*, 67(12), 2545-2551.

[16] Saleh M.M. S, Dhamad G. D, and Kamel L. AE. (2014). Inflammatory markers mediated diabetic nephropathy in patients with type 1 and type 2 diabetes mellitus. *Fac Med Baghdad*, 56, (4):401-404.

[17] Pearson-Stuttard, J. et al. (2016) Diabetes and infection: assessing the association with glycaemic control in population-based studies, *The lancet Diabetes & endocrinology*, 4(2), pp. 148–158.

[18] Harms, R. Z., Yarde, D. N., Guinn, Z., Lorenzo-Arteaga, K. M., Corley, K. P., Cabrera, M. S., & Sarvetnick, N. E. (2015). Increased expression of IL-18 in the serum and islets of type 1 diabetics. *Molecular immunology*, 64(2), 306-312.

[19] Ahmad, R., Thomas, R., Kochumon, S., & Sindhu, S.(2017). Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity. *Immunity, inflammation and disease*, 5(3), 318-335.

[20] Ali, Y., El-Gahel, H. E. S., Abdel-Hakem, N. E., El-Hefnawy, M. H., & Ebeid, M. E. (2018). Gene polymorphism of Il-18 as a pro-inflammatory mediator and susceptibility of diabetes type 1 in Egyptian children. *Research Journal of Applied Biotechnology*, 4(2), 20-29.

[21] Hussein, I. A., AL-Abassi, H. M., & Nasser, A. A. (2017). IFN- γ T/A+ 874 Gene Polymorphism in Type 1 Diabetes Mellitus of Iraqi Children. *Ibn AL-Haitham Journal for Pure and Applied Science*, 29(1).

- [22] Majeed M N., (2008) Childhood Diabetes Mellitus In Thi-Qar city. *Iraqi Academic Scientific Journal*, (2), 1, 31-38.
- [23] Madha Mohammed Sheet Saleh, Ali Jabbar Edan, Sabah N Mohammed, (2012) Investigation of Certain Immunological Markers in First Degree Relatives of Type 1 Diabetic Patients. *Iraqi Academic Scientific Journal*. 11, (1), 62-70.
- [24] Apicella, M., Campopiano, M. C., Mantuano, M., Mazoni, L., Coppelli, A., & Del Prato, S. (2020). COVID-19 in people with diabetes: understanding the reasons for worse outcomes. *The Lancet Diabetes & Endocrinology*; 8; 782–92.
- [25] Elsehmawy, A. A. E. W., El-Toukhy, S. E., Seliem, N. M. A., Moustafa, R. S., & Mohammed, D. S. (2019). Apelin and chemerin as promising adipokines in children with type 1 diabetes mellitus. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*; 12:383-389.
- [26] Danne, T., Lüpke, K., Walte, K., Von Schuetz, W., & Gall, M. A. (2003). Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. *Diabetes care*, 26(11), 3087-3092.
- [27] Kandala, N. J., & Abdul Ridha, R. H. (2016). Association of genetic polymorphisms in a sample of Iraqi patients with type 1 diabetes mellitus. *Int J Curr Microbiol Appl Sci*, 5, 725-732.
- [28] Derraik, J. G., Reed, P. W., Jefferies, C., Cutfield, S. W., Hofman, P. L., & Cutfield, W. S. (2012). Increasing incidence and age at diagnosis among children with type 1 diabetes mellitus over a 20-year period in Auckland (New Zealand). *PLoS One*, 7(2), e32640.
- [29] Wherrett, D., Huot, C., Mitchell, B., Pacaud, C. D. (2000). Type 1 Diabetes in Children and Adolescents. *Canadian Diabetes Association Clinical Practice Guidelines Expert Committee*, 12(2): 1-3.
- [30] Dong, G., Liang, L., Fu, J., & Zou, C. (2007). Serum interleukin-18 levels are raised in diabetic ketoacidosis in Chinese children with type 1 diabetes mellitus. *Indian Pediatrics*, 44(10), 732.
- [31] Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., ... & Giugliano, D. (2002). Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation*, 106(16), 2067-2072.
- [32] Yasir SJ, Abbas HH, Al-heidery ZH (2013): Screening of Human Cytomegalovirus (CMV) in Diabetic Patients in Najaf Governorate, *Medical Journal of Babylon*; 10(1):236-244.
- [33] Ahmad-Abakur EH, Abdelkareem MA, Abraham-Holi, Mohamed A, Ali A (2014): Associations of cytomegalovirus with type I diabetes mellitus among children in Khartoum State, *African J Microbiol Res*; 8(16):1730–1734.
- [34] Abdel-Moneim, A., El-Senousy, W. M., Abdel-Latif, M., Khalil, R. G., & Arafa, A. A. (2017). Increased incidence of Anti-IgG of Coxsackievirus and cytomegalovirus among diabetic children in Egypt. *International Journal of Bioassays*, 6(9), 5489-93.
- [35] Al-Hakami, A. M., Shati, A. A., Alsuheel, A. M., Hakami, A. R., Al Qahtani, M. A., Jelban, H. M., & Ali, A. S. (2016). Seroprevalence of human cytomegalovirus antibodies among children with type I diabetes mellitus in the Aseer Region, Southwest KSA. *Journal of Taibah University Medical Sciences*, 11(4), 388-394.
- [36] Aarnisalo, J., Veijola, R., Vainionpää, R., Simell, O., Knip, M., & Ilonen, J. (2008). Cytomegalovirus infection in early infancy: risk of induction and progression of autoimmunity associated with type 1 diabetes. *Diabetologia*, 51(5), 769-772.
- [37] Dedinská, I., Laca, L., Miklušica, J., Kantárová, D., Galajda, P., & Mokán, M. (2016). Correlation between CMV infection and post-transplantation new-onset diabetes mellitus. *International journal of organ transplantation medicine*, 7(3), 173-182.
- [38] Yoon, J. W., Ihm, S. H., & Kim, K. W. (1989). Viruses as a triggering factor of type 1 diabetes and genetic markers related to the susceptibility to the virus-associated diabetes. *Diabetes research and clinical practice*, 7, S47-S58.
- [39] Yoneda, S., Imagawa, A., Fukui, K., Uno, S., Kozawa, J., Sakai, M., ... & Shimomura, I. (2017). A histological study of fulminant type 1 diabetes mellitus related to human cytomegalovirus reactivation. *The Journal of Clinical Endocrinology & Metabolism*, 102(7), 2394-2400.

دور الانترلوكين-18 والفيروس المضخم للخلايا البشرية في داء السكري من النوع الأول في محافظة ذي قار

علي غالب عمار¹، مهدي حسن محمود¹، هند مزهر موسى²

¹قسم علوم الحياة، كلية العلوم، جامعة تكريت، تكريت، العراق

²قسم التحليلات المرضية، كلية العلوم، جامعة ذي قار، ذي قار، العراق

الملخص

أشارت الدراسات السابقة إلى أن مستويات المصل المرتفعة من إنترلوكين-18 والاجسام المضادة أم وكذلك جي للفيروس المضخم للخلايا البشرية والتي كان لها دور أساسي في امراضية السكري من النوع الاول. لذلك كان الهدف من الدراسة الحالية هو التحقيق في التداخل المحتمل بين الفيروس المضخم للخلايا البشري وأنترلوكين-18 المتسببان في امراضية السكري من النوع الاول. تم استخدام مصل (45) مريضاً بداء السكري من النوع الاول و (45) شخص سليم كعينات سيطرة للكشف عن مستويات الأنترلوكين-18 باستخدام عدة الاليزا ELISA والكشف عن الاجسام المضادة أم وكذلك جي للفيروس المضخم للخلايا البشرية باستخدام جهاز cobas c411 .

اظهرت النتائج بارتفاع مستويات المصل لأنترلوكين-18 والاجسام المضادة أم وكذلك جي للفيروس المضخم للخلايا البشرية حيث كان أعلى بشكل ملحوظ في مرضى السكري النوع الأول مقارنة بمجموعة السيطرة (12.196 ± 45.8773 و 0.25 ± 0.52 , 13.0 ± 63.52 بيكوغرام / مل للمرضى على التوالي) مقابل (3.9 ± 12.611 و 0.01 ± 0.11 , 0.68 ± 0.261 بيكوغرام / مل للأصحاء على التوالي); وكانت القيم عند $P \text{ value} \leq 0.05$. خلصت نتائج البيانات إلى أن هناك زيادة كبيرة للإنترلوكين-18 والاجسام المضادة أم وكذلك جي للفيروس المضخم للخلايا البشرية في مصل مجموعة المرضى مقارنة بالمستويات الأقل في المجموعة الضابطة، مما يشير إلى أن هذه العلامات قد تكون متورطة في التسبب بأمراضية وتطور داء السكري من النوع الأول.